Clinical Trials
57 trialsDESCENT-1
A2 Biotherapeutics Inc.
LEARN
University of Sydney
iCaRe2
University of Nebraska
DP-04
AstraZeneca
BASECAMP-1
A2 Biotherapeutics Inc.
TraveraRTGx
Travera Inc
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
(CLOCS-2)
Imperial College London
ORI-EGI-03
Origin Sciences
MOMENTUM
UMC Utrecht
Operative Risk After Pancreatic Surgery in Patients With End Stage Renal Disease
National Taiwan University Hospital
CAMPERR
Adela, Inc
SCORE
Natera, Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
Memorial Sloan Kettering Cancer Center
OLAP
AstraZeneca
DELFI-L101
Delfi Diagnostics Inc.
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
Abramson Cancer Center at Penn Medicine
PREVAILctDNA
Royal Marsden NHS Foundation Trust
PREFER
Labcorp Corporation of America Holdings, Inc
INSPIRE
Singlera Genomics Inc.
MOHCCN-O
University Health Network, Toronto
ROOT
Taproot Health
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
RADIANT
DxTerity Diagnostics
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Beijing Friendship Hospital
ONFM-SBRT
Peking University Third Hospital
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
CADENCE
MiRXES Pte Ltd
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
Wuhan Ammunition Life-tech Co., Ltd
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Exact Sciences Corporation
WiZen
Technische Universität Dresden
PASSION
Assistance Publique - Hôpitaux de Paris
SPACE2
Weprom
HSP70CTC
Charite University, Berlin, Germany
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
University of Southern California
PIONEER
SpeciCare
NIRPA
Gary Onik MD
Cancer Development In Organ Transplant Recipients
University of Zurich
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
N1
CureOne
ACRIN7151
American College of Radiology Imaging Network
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Cota Inc.
Cancer in Patients With Gabapentin (GPRD)
GlaxoSmithKline
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
Wake Forest University Health Sciences
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
GlaxoSmithKline